Osteseconazole: First FDA-approved drug for recurrent vulvovaginal candidiasis
Osteseconazole: First FDA-approved drug for recurrent vulvovaginal candidiasis Around 75% of all adult women will have at least 1 yeast infection during their lifetime. About half of them will have a recurrence of the condition and 9% of them may develop recurrent vulvovaginal candidiasis (RVVC). According to CDC, RVVC is defined as three or more […]
FDA Approvals